Sommetrics develops and commercializes the aerSleep® family of negative-pressure sleep-therapy devices to treat obstructive sleep apnea. The company’s aerSleep® II is a self-contained unit that applies mild external vacuum over the upper airway, is quiet, held in place without a retaining strap, and does not generate infectious aerosols. aerSleep® II is designated a Breakthrough Device by the FDA and builds on favorable results from the first-generation aerSleep® (Health Canada Medical Device License). The company cites 33 issued patents (with additional patents pending) covering its aer+® technology and a proprietary skin-friendly interface material. Sommetrics has launched the SUPRA pivotal clinical trial under an FDA Investigational Device Exemption at 10 U.S. sleep centers to evaluate treatment benefits and safety in moderate-to-severe OSA patients unable to use CPAP, with responders followed for 24 weeks of home use. The company is privately funded and located in San Diego, California. Sommetrics develops products and services aimed at enhancing health and well-being by improving sleep quality, with a focus on disorders caused by narrowing or closure of the upper airway. The company’s proprietary aer+™ (aer±) technology product line targets issues such as obstructive sleep apnea and chronic snoring. Sommetrics has an FDA-cleared and CE-marked acute care product that addresses airway narrowing commonly caused by mild to moderate sedation. The company is privately funded and based in San Diego. The recently completed financing will be used to complete development of the company’s product offerings and to obtain additional regulatory approvals. Leadership frames the work as addressing sleep quality as a key determinant of overall health.

Total raised

$23M

Funding rounds

2

Latest round

Series C

Latest activity

Sep 2021